Real-World Evidence In COPD: German Real-World Analysis - Background

• Identify gaps in real-world evidence on dupilumab in COPD, including small patient populations and limited registry data
• Explain how the German multicenter study aims to complement phase 3 trial evidence in routine clinical practice
• Describe the study’s focus on exacerbation severity, clinical phenotypes, patient-reported outcomes, and lung function beyond spirometry

Real-world evidence can complement clinical trial findings by examining treatment in the heterogeneous populations seen in routine clinical practice. In video 2 of this three-part series, hear Dr. Mustafa Abdo discuss the rationale for a retrospective multicenter study of patients with COPD treated with dupilumab across Germany. Learn about the evidence gaps the study addresses and its aims, including evaluating severe exacerbations requiring hospitalization, exploring outcomes across different clinical phenotypes, and assessing patient-reported outcomes and lung function measures beyond spirometry.